Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04788264
Other study ID # 20D.775
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 28, 2021
Est. completion date June 29, 2023

Study information

Verified date November 2023
Source Thomas Jefferson University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This clinical trial evaluates the tolerability of a physical activity program in head and neck cancer patients who are undergoing cancer treatment. The goal of this trial is to give patients exercises prescribed by a physical therapist that they are able to complete regularly at home. Increasing physical activity may help patients reduce fatigue, improve mood, increase physical performance, and decrease joint pain.


Description:

PRIMARY OBJECTIVE: I. To compare the changes in physical activity between the control and intervention groups of patients with head and neck or lung cancer at 6-weeks and 12-weeks, compared to baseline. SECONDARY OBJECTIVES: I. To demonstrate the feasibility, engagement, retention, and acceptability of physical activity promotion (intervention) in patients with head and neck or lung cancer. II. To calculate the effect sizes for the differences between the control and intervention in daily changes in psychosocial outcomes at 6-weeks and 12-weeks, compared to baseline. EXPLORATORY OBJECTIVE: I. To calculate the effect sizes for the differences between the control and intervention in changes in immunomodulatory, metabolic and aging biomarkers at 6-weeks and 12-weeks, compared to baseline. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Beginning 1 week prior to start of intervention, patients receive a Fitbit to monitor physical activity for 13 weeks. Patients receive consultation and personalized exercise prescription from a physical therapist at baseline, and attend exercise training sessions with a physical therapist during weeks 1, 3, 6, 9, and 12. Patients also attend behavior modification sessions with a behavioral therapist that focus on goal setting and healthy behavior changes during weeks 2, 4, 5, 7, 8, 10, and 11. ARM II: Patients receive a Fitbit to monitor physical activity for 12 weeks. Patients also receive consultation from a physical therapist to assess physical performance at weeks 1, 6, and 12. After completion of study intervention, patients are followed up at 30 days. EXPLORATORY OBJECTIVE: I. To demonstrate the difference in the magnitude of physical activity improvements between the immunotherapy and chemo-immunotherapy patients. OUTLINE: Beginning 1 week prior to start of intervention, patients receive a Fitbit to monitor physical activity for 13 weeks. Patients receive consultation and personalized exercise prescription from a physical therapist at baseline, and attend exercise training sessions with a physical therapist during weeks 1, 3, 6, 9, and 12. Patients also attend behavior modification sessions with a behavioral therapist that focus on goal setting and healthy behavior changes during weeks 2, 4, 5, 7, 8, 10, and 11. After completion of study intervention, patients are followed up at 30 days.


Recruitment information / eligibility

Status Completed
Enrollment 12
Est. completion date June 29, 2023
Est. primary completion date June 29, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Diagnosed with head and neck cancer including cancers of the sinuses, oral cavity, oropharynx, hypopharynx, or larynx (all stages); therapeutically eligible to receive at least three months of immunotherapy - Medically cleared by oncologist to engage in aerobic and resistance exercise intervention - 18 years of age or older - Access to a smartphone and have an active wi-fi connection at home - Able to read and/or to speak English - Able to comprehend and sign a written informed consent (no cognitive decline) - Women of reproductive potential must have a negative serum or urine pregnancy test within the week prior to starting therapy Exclusion Criteria: - Severe or unstable cardiopulmonary, metabolic, or renal disease as determined by the referring oncologist - Unable to walk safely without physical assistance of another person - Any condition that may limit the ability to comply with behavioral recommendations of the program - Pregnant or planning a pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Medical Device Usage and Evaluation
Receive Fitbit
Consultation
Receive consultation from a physical therapist
Exercise Intervention
Attend exercise training sessions
Behavioral:
Behavioral Intervention
Attend sessions with a behavioral therapist
Other:
Questionnaire Administration
Ancillary studies
Quality of Life Assessment
Ancillary studies

Locations

Country Name City State
United States Thomas Jefferson University Hospital Philadelphia Pennsylvania

Sponsors (1)

Lead Sponsor Collaborator
Thomas Jefferson University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in Fitbit-recorded average steps (moderate and/or intensive) per day, each day Changes in physical activity of the intervention group at 6-weeks and 12-weeks, compared to baseline, using two-sample t-tests, respectively. Longitudinal models such as (non)linear mixed models or generalized estimating equation (GEE) models Baseline to 12 weeks after physical activity promotion
Primary Change in Fitbit-recorded average steps (moderate and/or intensive) per day, each day Changes in physical activity of the control group at 6-weeks and 12-weeks, compared to baseline, using two-sample t-tests, respectively. Longitudinal models such as (non)linear mixed models or generalized estimating equation (GEE) models Baseline to 12 weeks after physical activity promotion
Primary Change in Fitbit-recorded average active minutes (moderate and/or intensive) per day, each day time trend will be compared between control and intervention groups at 6-weeks and 12-weeks, compared to baseline, using two-sample t-tests, respectively. Longitudinal models such as (non)linear mixed models or generalized estimating equation (GEE) models Baseline to 12 weeks after physical activity promotion
See also
  Status Clinical Trial Phase
Terminated NCT04110249 - Photoacoustic Imaging for Measuring Tumors and Normal Tissue in Patients With Head and Neck Cancer N/A
Completed NCT01831089 - Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors Phase 1
Completed NCT03663985 - FALCOn (Facteur AnthropoLogique Cancer Orl)
Recruiting NCT05544136 - A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer Phase 2
Recruiting NCT05077072 - Interdisciplinary Interventions to Address Pain Management Among Head and Neck Cancer Patients Phase 2
Recruiting NCT04151082 - High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors Phase 1/Phase 2
Completed NCT03964896 - Nurse-Driven Telephone Intervention in Improving Side Effects in Cancer Patients Undergoing Chemotherapy N/A
Recruiting NCT04147494 - Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues Early Phase 1
Completed NCT02474095 - Acupuncture-Like Transcutaneous Electrical Nerve Stimulation in Treating Radiation-Induced Xerostomia in Patients With Head and Neck Cancer N/A
Withdrawn NCT03261180 - Nestle Impact Advanced Recovery in Improving Surgery Recovery in Patients With Head and Neck Cancer N/A
Terminated NCT04618432 - Collection of Clinical Data and Specimens for Research on Head and Neck and Communication Disorders
Active, not recruiting NCT02615275 - Bioelectrical Impedance Analysis in Estimating Body Composition in Patients With Stage I-IV Head and Neck Cancer Undergoing Radiation Therapy N/A
Terminated NCT05012397 - Milademetan in Advanced/Metastatic Solid Tumors Phase 2
Recruiting NCT00991094 - Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated With Proton Therapy
Recruiting NCT04870762 - Customized 3D Printed Oral Stents During Head and Neck Radiotherapy Phase 2
Completed NCT02369835 - Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy Phase 3
Completed NCT03902535 - Geriatric and Quality of Life Assessments in Older Patients With Non-metastatic or Metastatic Head and Neck or Lung Cancer Undergoing Surgery or Chemoradiation and Their Caregivers
Recruiting NCT05526924 - Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer Phase 1
Recruiting NCT03795610 - Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma Phase 2
Recruiting NCT06420219 - An Integrative Multi-Omic Characterization of Head and Neck Carcinogenesis, Progression and Recurrence